2 ms·
The problem is that we don’t have the range of treatment types to target all the the different mutation types. Most of the drugs we have target the same basic p
by danieltillett 11y ago
The problem is that we don’t have the range of treatment types to target all the the different mutation types. Most of the drugs we have target the same basic pathways like DNA damage repair - we have dozens of these drugs, but very few targeting specific mutations. We need a lot more diversity of action in our drugs if we have a chance to cure cancer.
Having said this the most hopeful area is the immunotherapies. Scaled out to their full potential we could have a very powerful set of drugs to go after the cancer diversity problem.